Q4 2025 · 13F-HR
Atle Fund Management ABholdings as filed
Filed 2026-02-06 · accession 0001381843-26-000002
$313.4M
Reported value
39
Positions
2025-12-31
Period end
The Brief · Atle Fund Management AB · Q4 2025
AI · grounded in 13F
Atle Fund Management AB closed its position in Edwards Lifesciences Corp EW, reducing its exposure by $542,105. The fund also exited positions in Merus N.V. 2GH and Harmony Bioscience Holdings HRMY. On the buy side, the fund increased its holdings in Merck & Co. Inc MRK by 21.66% and AbbVie Inc ABBV by 17.45%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 532457108 | LLY | Eli Lilly & Co | $33.5M | 10.7% | 31,133 | Common | SOLE |
| 00287Y109 | ABBV | AbbVie Inc | $24.7M | 7.89% | 108,181 | Common | SOLE |
| 58933Y105 | MRK | Merck & Co. Inc | $20.6M | 6.57% | 195,768 | Common | SOLE |
| 883556102 | TMO | Thermo Fisher Scientific Corp | $17.3M | 5.53% | 29,915 | Common | SOLE |
| 64125C109 | NBIX | Neurocrine Biosciences Inc | $13.4M | 4.29% | 94,796 | Common | SOLE |
| 46120E602 | ISRG | Intuitive Surgical Inc | $12.6M | 4.03% | 22,322 | Common | SOLE |
| 07725L102 | ONC | BEONE MEDICINES LTD-ADR | $12.3M | 3.92% | 40,432 | Common | SOLE |
| 10806X102 | BBIO | Bridgebio Pharma Inc | $10.8M | 3.45% | 141,296 | Common | SOLE |
| 92532F100 | VRTX | Vertex Pharmaceuticals Inc | $10.4M | 3.32% | 22,984 | Common | SOLE |
| 101137107 | BSX | Boston Scientific Corp | $10.4M | 3.31% | 108,682 | Common | SOLE |
| 863667101 | SYK | Stryker Corporation | $9.4M | 3.01% | 26,835 | Common | SOLE |
| 126650100 | CVS | CVS HEALTH CORP | $8.5M | 2.70% | 106,518 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc | $8.3M | 2.66% | 33,853 | Common | SOLE |
| 03073E105 | COR | Cencora Inc | $8.0M | 2.56% | 23,773 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $7.3M | 2.33% | 92,377 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION Medicines Inc | $7.2M | 2.29% | 90,184 | Common | SOLE |
| 031162100 | AMGN | Amgen Inc | $7.2M | 2.29% | 21,903 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $7.1M | 2.26% | 89,685 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $7.0M | 2.23% | 70,851 | Common | SOLE |
| N62509109 | NAMS | NewAmsterdam Pharma Co NV | $6.9M | 2.21% | 197,036 | Common | SOLE |
| G01767105 | ALKS | Alkermes PLC | $6.8M | 2.16% | 242,473 | Common | SOLE |
| 450056106 | IRTC | iRhythm Technologies Inc | $6.7M | 2.13% | 37,579 | Common | SOLE |
| 375558103 | GILD | Gilead Sciences Inc | $6.2M | 1.99% | 50,796 | Common | SOLE |
| 902673102 | UFPT | UFP Technologies Inc | $5.1M | 1.63% | 22,986 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $4.9M | 1.55% | 27,873 | Common | SOLE |
| 14149Y108 | CAH | Cardinal Health Inc | $4.8M | 1.54% | 23,470 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $4.3M | 1.36% | 31,590 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $4.2M | 1.33% | 41,831 | Common | SOLE |
| 254604101 | IRON | Disc medicine inc | $3.8M | 1.22% | 47,967 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $3.4M | 1.07% | 97,438 | Common | SOLE |
| 91324P102 | UNH | Universal Health Services Inc | $3.2M | 1.02% | 14,636 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $3.1M | 1.00% | 584,332 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $2.9M | 0.93% | 62,735 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx Inc | $2.7M | 0.87% | 41,717 | Common | SOLE |
| 252131107 | DXCM | Dexcom Inc | $2.6M | 0.84% | 39,722 | Common | SOLE |
| 05280R100 | AUTL | Autolus Therapeutics PLC | $2.3M | 0.74% | 1,169,634 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $1.9M | 0.60% | 111,363 | Common | SOLE |
| 21833P301 | CRBP | Corbus Pharmaceuticals Holding | $873,055 | 0.28% | 107,255 | Common | SOLE |
| 747324101 | PYXS | PYXIS ONCOLOGY INC | $709,831 | 0.23% | 617,245 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.